Two high-growth stocks you might regret not buying

You could miss out on thousands of pounds of gains by overlooking these two companies.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Growth Trees

Image: Public domain

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Over the past decade, RPC (LSE: RPC) has proven itself to be one of the market’s top growth champions. Indeed, if you’d invested in the business 10 years ago with £1,000, today that would be worth £4,431 today, including dividends. 

The plastic packaging maker has been able to achieve such impressive returns for investors as the business is highly profitable and cash generative. Management has been able to successfully reinvest that cash in acquisitions to help improve growth further. The largest of these deals was the recent $640m acquisition of US-based plastic food packaging manufacturer Letica Group, announced in February, which was at the time the sixth deal in five months. 

Growth through acquisitions 

These deals have paid off handsomely. Today, the group announced that during the six months to the end of September, revenue grew 53% year-on-year to £1.9bn, reflecting the contribution from acquisitions, and adjusted EBITDA rose 49%. Free cash flow was up 45% to £172m, from £118m the year before, giving management room to hike the interim payout by 28%. 

After a busy start to the year, RPC is now focused on optimising its cost structure, paying down debt and integrating existing acquisitions. According to management, there will be no further deals this year

Still, RPC does not need to buy to grow. Healthy cash generation gives the group plenty of scope to reinvest in the business and grow organically (management is also using cash to buy back stock). 

City analysts have pencilled in earnings per share growth of 11% for the fiscal year ending 31 March 2018, implying that the shares are trading at an estimated forward P/E of 13.4. I believe that this lowly valuation undervalues RPC and the group’s prospects considering the firm’s historical growth rate. The shares also support a dividend yield of 2.9%, and RPC has a 26-year record of increasing its payout to investors. 

Doubling profits 

Another growth stock I believe you might regret not buying is Quixant (LSE: QXT). 

Quixant is an exciting business. The firm manufactures specialist computer systems, which is proving to be highly lucrative. Earnings per share jumped 44% last year, and are on track to grow 36% this year, thanks to rising demand. 

In fact looking at the firm’s first-half results, I believe that the City’s estimate for growth of 36% for 2017 might be conservative. For the six months to 30 June, group revenue rose 38%, while EBITDA and pre-tax profit lept 74% and 98%, respectively. Management has cautioned that these strong growth numbers might not be repeated in the second half as H1 demand was “out of the ordinary” and such buoyant trading is unlikely to be repeated. Still, these numbers put the group in a great position to be able to hit full-year targets. 

The one downside with Quixant is that the shares are quite expensive. At the time of writing the stock is trading at a forward P/E of 29.9, although when you factor in the projected earnings growth for this year, the shares seem cheap, trading at a PEG ratio of 0.8.

Rupert Hargreaves does not own any share mentioned. The Motley Fool UK has recommended RPC Group. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Close-up of British bank notes
Investing Articles

£20,000 for a Stocks and Shares ISA? Here’s how to try and turn it into a monthly passive income of £493

Hundreds of pounds in passive income a month from a £20k Stocks and Shares ISA? Here's how that might work…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£5,000 put into Nvidia stock last Christmas is already worth this much!

A year ago, Nvidia stock was already riding high -- but it's gained value since. Our writer explores why and…

Read more »

Investing Articles

Are Tesco shares easy money heading into 2026?

The supermarket industry is known for low margins and intense competition. But analysts are bullish on Tesco shares – and…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Can this airline stock beat the FTSE 100 again in 2026?

After outperforming the FTSE 100 in 2025, International Consolidated Airlines Group has a promising plan to make its business more…

Read more »

Investing Articles

1 Stocks and Shares ISA mistake that will make me a better investor in 2026

All investors make mistakes. The best ones learn from them. That’s Stephen Wright’s plan to maximise returns from his Stocks…

Read more »

Portrait Of Senior Couple Climbing Hill On Hike Through Countryside In Lake District UK Together
Investing Articles

I asked ChatGPT if £20,000 would work harder in an ISA or SIPP in 2026 and it said…

Investors have two tax-efficient ways to build wealth, either in a Stocks and Shares ISA or SIPP. Harvey Jones asked…

Read more »

Investing Articles

How much would I need invested in an ISA to earn £2,417 a month in passive income?

This writer runs the numbers to see what it takes in an ISA to reach £2,417 a month in passive…

Read more »

Investing Articles

Rolls-Royce shares or Melrose Industries: Which one is better value for 2026?

Rolls-Royce shares surged in 2025, surpassing most expectations. Dr James Fox considers whether it offers better value than peer Melrose.

Read more »